Advertisement

Topics

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma

18:56 EDT 23 Aug 2017 | Biotech-Finances

Wednesday, August 23rd 2017 at 12:00pm UTC – First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – – Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Unum Therapeutics Inc., a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple …

Cet article Unum Therapeutics Announces Active Investigational New Drug (IND)
Application for ACTR087 in Combination with SEA-BCMA in Patients with
Relapsed/Refractory Multiple Myeloma
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...